Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions.
暂无分享,去创建一个
Dan Peer | Biana Godin | Ji-Ho Park | Erkki Ruoslahti | Hamidreza Ghandehari | Yechezkel Barenholz | Dorothy Farrell | Paolo Decuzzi | Diana Boraschi | Marina A Dobrovolskaia | S Moein Moghimi | Julia Ljubimova | P. Decuzzi | Y. Barenholz | A. Gabizon | D. Peer | E. Ruoslahti | Ji-Ho Park | N. Serkova | T. Anchordoquy | D. Simberg | B. Godin | Z. S. Farhangrazi | S. Moghimi | J. Ljubimova | M. Dobrovolskaia | L. Pagliaro | H. Ghandehari | D. Boraschi | D. Farrell | Dmitri Simberg | Alberto Gabizon | Michael Chorny | Len Pagliaro | Thomas J Anchordoquy | M. Chorny | N. M. La‐Beck | Natalie J Serkova | Ninh M La-Beck | Z Shadi Farhangrazi | Z. Farhangrazi | S. Moghimi | Natalie J. Serkova | Natalie J. Serkova
[1] H. Hochster,et al. Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. , 2010, Anticancer research.
[2] S M Moghimi,et al. Cancer nanomedicine and the complement system activation paradigm: anaphylaxis and tumour growth. , 2014, Journal of controlled release : official journal of the Controlled Release Society.
[3] Mark E. Davis,et al. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles , 2009, Proceedings of the National Academy of Sciences.
[4] S. Moghimi,et al. Just so stories: the random acts of anti-cancer nanomedicine performance. , 2014, Nanomedicine : nanotechnology, biology, and medicine.
[5] I. Alferiev,et al. Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy. , 2015, Biomaterials.
[6] L. Pagliaro,et al. Photothermal therapy using gold nanorods and near-infrared light in a murine melanoma model increases survival and decreases tumor volume , 2014 .
[7] Marina A. Dobrovolskaia,et al. Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory. , 2013, Integrative biology : quantitative biosciences from nano to macro.
[8] K. Alitalo,et al. Lymphatic vessels regulate immune microenvironments in human and murine melanoma. , 2016, The Journal of clinical investigation.
[9] Erkki Ruoslahti,et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. , 2009, Cancer cell.
[10] M. Ferrari,et al. Redirecting Transport of Nanoparticle Albumin-Bound Paclitaxel to Macrophages Enhances Therapeutic Efficacy against Liver Metastases. , 2016, Cancer research.
[11] James E Bear,et al. Nanoparticle clearance is governed by Th1/Th2 immunity and strain background. , 2013, The Journal of clinical investigation.
[12] F. Kiessling,et al. Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[13] Hamidreza Ghandehari,et al. High intensity focused ultrasound hyperthermia for enhanced macromolecular delivery. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[14] S. Goldberg,et al. Therapeutic Efficacy of Combining PEGylated Liposomal Doxorubicin and Radiofrequency (RF) Ablation: Comparison between Slow-Drug-Releasing, Non-Thermosensitive and Fast-Drug-Releasing, Thermosensitive Nano-Liposomes , 2014, PloS one.
[15] Tracy K. Pettinger,et al. Nanopharmaceuticals (part 1): products on the market , 2014, International journal of nanomedicine.
[16] M. Machluf,et al. Nanoghosts as a Novel Natural Nonviral Gene Delivery Platform Safely Targeting Multiple Cancers. , 2016, Nano letters.
[17] Mauro Ferrari,et al. Enhanced performance of macrophage-encapsulated nanoparticle albumin-bound-paclitaxel in hypo-perfused cancer lesions. , 2016, Nanoscale.
[18] F M Muggia,et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] A. J. Tavares,et al. Analysis of nanoparticle delivery to tumours , 2016 .
[20] Ashley M. Laughney,et al. Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle , 2015, Science Translational Medicine.
[21] A. Gabizon,et al. Liposome promotion of tumor growth is associated with angiogenesis and inhibition of antitumor immune responses. , 2015, Nanomedicine : nanotechnology, biology, and medicine.
[22] Samir Mitragotri,et al. Impact of particle elasticity on particle‐based drug delivery systems☆ , 2017, Advanced drug delivery reviews.
[23] Jaehong Key,et al. Soft Discoidal Polymeric Nanoconstructs Resist Macrophage Uptake and Enhance Vascular Targeting in Tumors. , 2015, ACS nano.
[24] Ji-Ho Park,et al. Liposome-based engineering of cells to package hydrophobic compounds in membrane vesicles for tumor penetration. , 2015, Nano letters.
[25] M. Dobrovolskaia,et al. Endotoxin and Engineered Nanomaterials , 2013 .
[26] Janos Szebeni,et al. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. , 2005, Toxicology.
[27] A. Gabizon,et al. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. , 2016, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[28] Kinam Park,et al. Targeted drug delivery to tumors: myths, reality and possibility. , 2011, Journal of controlled release : official journal of the Controlled Release Society.
[29] H. Maeda,et al. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.
[30] V. M. Holers,et al. Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake. , 2015, ACS nano.
[31] D. Peer,et al. Immunomodulation of hematological malignancies using oligonucleotides based-nanomedicines. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[32] Mauro Ferrari,et al. Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.
[33] Morteza Mahmoudi,et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. , 2016, Nature nanotechnology.
[34] A. Gabizon,et al. Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy. , 2016, International Journal of Radiation Oncology, Biology, Physics.
[35] Yechezkel Barenholz,et al. In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site. , 2015, Nanomedicine : nanotechnology, biology, and medicine.
[36] R. Thorpe,et al. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials — Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm , 2015, Journal of immunological methods.
[37] S. Moein Moghimi,et al. Nanomedicine and the complement paradigm. , 2013, Nanomedicine : nanotechnology, biology, and medicine.
[38] Y. Barenholz,et al. Coencapsulation of alendronate and doxorubicin in pegylated liposomes: a novel formulation for chemoimmunotherapy of cancer , 2016, Journal of drug targeting.
[39] S. Alzghari,et al. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. , 2016, Journal of controlled release : official journal of the Controlled Release Society.
[40] Mina J. Bissell,et al. The perivascular niche regulates breast tumor dormancy , 2013, Nature Cell Biology.